Clinical trials: Cushing Syndrome
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Adrenal Tumor, Adrenal Disease
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases.
- Conditions
- Adrenal Tumor, Adrenal Disease, Adrenal Mass, Adrenalectomy; Status
- Trial name
- NCT06050057
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Olomouc
Cushing Syndrome, Hypercortisolism
Nailfold Capillaroscopy Evaluation in Cushing Syndrome Patients
This cross-sectional, single-center study will assess the microvascular function using a nailfold video-capillaroscopy in patients with endogenous Cushing syndrome.
- Trial name
- NCT04433819
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Marmara University
Mineralocorticoid Excess, Primary Aldosteronism
Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism
This study is a observational study applying 24-hour microdialysis methodology to perform dynamic multisteroid adrenal hormone profiling of patients with suspected or confirmed PA.
- Conditions
- Mineralocorticoid Excess, Primary Aldosteronism, Hypercortisolism
- Trial name
- NCT06495983
- Testing
- dynamic microdialysis sampling
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Hyperaldosteronism, Hypercortisolism
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works.
- Conditions
- Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
- Trial name
- NCT06246357
- Testing
- [68Ga]Ga-PentixaFor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Obesity, Morbid
Study of the Steroid Hormone Milieu in Obese Patients
The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal…
- Trial name
- MiSterO (NCT06341699)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Istituto Auxologico Italiano
Adrenal Incidentaloma, Hypercortisolism
Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations
The investigators hypothesize that cardiovascular and metabolic alterations can occur in patients with adrenal adenomas and possible Autonomous Cortisol Secretion (pACS).
- Conditions
- Adrenal Incidentaloma, Hypercortisolism, Adrenal Tumor
- Trial name
- ITACA (NCT04127552)
- Testing
- Adrenalectomy
- Where
- Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Iatrogenic Cushing's Disease
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition
Currently, 2-3% of the population of the United Kingdom and United States of America receive glucocorticoid therapy. Significant adverse effects are not confined to chronic use; recurrent short-course administration is associated…
- Trial name
- TICSI (NCT03111810)
- Testing
- AZD4017 and prednisolone
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
Cushing Syndrome
Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure
In this study, we aimed to determine a specific cut-off value for 1mg DST to prevent false positivity usually seen in CRF patients according to the standard cut-off value of 1.8 mcg/dl.
- Trial name
- NCT05568602
- Testing
- Dexamethasone suppression test
- Where
- Turkey (Türkiye)
- Volunteers
- 1,034 people
- Sponsor
- Marmara University
Endocrine System Disease, Cardiovascular Imaging
Cardiac Steatosis in Cushing's Syndrome
This study aims at evaluating the myocardial triglyceride content and cardiac structure and function, using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging, in patients with Cushing's syndrome before and…
- Trial name
- CORTICOEUR (NCT02202902)
- Testing
- 1H magnetic resonance spectroscopy and CMRI
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Endocrine Disorders, Hypertension
EndoSense: Continuous Real-Time Monitoring of Health Markers in Endocrine and Metabolic Disorders
The goal of this trial is to learn whether wearable devices and hormone sampling can measure how the body changes during daily-life challenges in adults with endocrine or metabolic disorders.
- Conditions
- Endocrine Disorders, Hypertension, Primary Aldosteronism, Cortisol Excess
- Trial name
- EndoSense (NCT07727356)
- Testing
- Sequential Dietary Sodium Modulation
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Felix Beuschlein
Adrenal Incidentalomas, Cushing Syndrome
Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome
Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome
- Trial name
- NCT06801249
- Testing
- Metarapone, Standardized antihypertensive therapy
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome Related to Cortisolic Adenoma
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the…
- Trial name
- LIPOCUSH (NCT01688349)
- Testing
- analyze the role of glucocorticoid in AT distribution.
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Endogenous Cushing's Syndrome
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess…
- Trial name
- NCT03277690
- Testing
- Levoketoconazole
- Where
- 45 sites in United States, Bulgaria and 10 more
- Volunteers
- 84 people
- Sponsor
- Cortendo AB
Hypercortisolism
Effects of Metyrapone in Patients With Hypercortisolism
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers…
- Trial name
- CEM (NCT05255900)
- Testing
- Metyrapone Capsules
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Auxologico Italiano
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
Mild Autonomous Cortisol Excess
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and…
- Trial name
- NCT05038878
- Testing
- Elagolix
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Icahn School of Medicine at Mount Sinai